Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Real-World Venetoclax-Obinutuzumab in 232 Treatment Naive CLL Patients: Feasibility and Tolerability

Blood (2023) 142 (Supplement 1): 4646.

https://doi.org/10.1182/blood-2023-186182

Published: 2023

Journal Articles

Long-Term Efficacy of a 6-Month Regimen of Rituximab and Lenalidomide in Follicular Lymphoma Patients in Need of First Therapy: Updated Analysis of the SAKK 35/10 Randomized Trial

Blood (2023) 142 (Supplement 1): 295.

https://doi.org/10.1182/blood-2023-173957

Published: 2023

Journal Articles

Pet-2 Positive during Frontline Therapy: An Early Unfavorable Predictor for Subsequent Salvage High-Dose Chemotherapy (HD-CT) and Autologous Stem Cell Transplant in Relapsed or Refractory Classical Hodgkin Lymphoma

Blood (2023) 142 (Supplement 1): 6179.

https://doi.org/10.1182/blood-2023-173085

Published: 2023

Journal Articles

Immune-Related Gene Expression Signatures Identify a Patient's Subset Achieving Durable Complete Response to Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma

Paulina Nierychlewska, Maria Rosaria Sapienza, Alessandro Davini, Eugenia Montanari, Anna Vanazzi, Simonetta Viviani, Valentina Tabanelli, Roberto Massimo Lemoli, Corrado Tarella, Stefano Pileri, Enrico Derenzini

Blood (2023) 142 (Supplement 1): 1644.

https://doi.org/10.1182/blood-2023-186819

Published: 2023

Journal Articles

Integration of Targeted Gene Expression Profiling and FDG-PET Radiomics Uncovers Radiometabolic Signatures Associated with Outcome in Diffuse Large B-Cell Lymphoma

Saveria Mazzara, Laura L. Travaini, Francesca Botta, Chiara Granata, Giovanna Motta, Federica Melle, Stefano Fiori, Valentina Tabanelli, Anna Vanazzi, Safaa M. Ramadan, Tommaso Radice, Sara Raimondi, Giuliana Lo Presti, Mahila E. Ferrari, Marta Cremonesi, Francesco Ceci, Corrado Tarella, Stefano A Pileri, Enrico Derenzini

Blood (2021) 138 (Supplement 1): 3496.

https://doi.org/10.1182/blood-2021-152679

Published: 2021

Journal Articles

Follicular Lymphoma Microenvironment Signatures Define Patients Subsets Obtaining Long Term Clinical Benefit after Single-Agent First-Line Anti-CD20 Immunotherapy

Enrico Derenzini, Marcello Del Corvo, Maria Chiara Quattrocchi, Marta Castelli, Maria Rosaria Sapienza, Saveria Mazzara, Stefano Fiori, Anna Vanazzi, Safaa M. Ramadan, Stefano A Pileri, Corrado Tarella

Blood (2021) 138 (Supplement 1): 3500.

https://doi.org/10.1182/blood-2021-153778

Published: 2021

Journal Articles

Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): The Experience at European Institute of Oncology (EIO)

Anna Vanazzi, MD, Safaa Ramadan, PhD MD, Francesca De Lorenzi, MD, Paola Arena, MD, Enrico Derenzini, MD PhD, Mario Rietjens, Anna Rotili, MD, Antuono Latronico, MD, Laura Travaini, MD, Emanuela Omodeo Sale', Daniela Malengo, Marianna Gerardi, Stefano Fiori, MD, Valentina Tabanelli, MD, Stefano A Pileri, Corrado Tarella, MD

Blood (2019) 134 (Supplement_1): 5283.

https://doi.org/10.1182/blood-2019-125239

Published: 2019

Journal Articles

Lymphoma Occurring during Pregnancy: Obstetric Outcome and Overall Survival in a Series of 19 Patients

Anna Vanazzi, MD, Fedro Peccatori, MD, Barbara Buonomo, MD, Di Loreto Eugenia, MD, Giovanna Scarfone, MD, Stefano A Pileri, Corrado Tarella, MD

Blood (2019) 134 (Supplement_1): 5289.

https://doi.org/10.1182/blood-2019-127391

Published: 2019

Journal Articles

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

Blood (2019) 134 (4): 353–362.

https://doi.org/10.1182/blood-2018-10-879643

Published: 2019

Includes: Supplemental data

Journal Articles

Integration of Nanostring Profiling and Functional Characterization of Oxidative and Replicative Stress Biomarkers Identifies Poor Prognosis MYC/BCL-2 Positive Diffuse Large B-Cell Lymphoma Subsets, Providing Opportunities for Precision Therapies

Enrico Derenzini, MD PhD, Alessandra Rossi, PhD, Claudio Agostinelli, MD, Maura Rossi, PhD, Federica Melle, PhD, Giovanna Motta, PhD, Marco Fabbri, PhD, Tommaso Radice, MD, Safaa Ramadan, PhD MD, Anna Vanazzi, MD, Valentina Tabanelli, MD, Stefano Fiori, MD, Annalisa Chiappella, MD, Alberto Agazzi, MD, Pier Luigi Zinzani, MD, Umberto Vitolo, Corrado Tarella, MD Prof, Stefano A. Pileri, MD PhD

Blood (2018) 132 (Supplement 1): 676.

https://doi.org/10.1182/blood-2018-99-118329

Published: 2018

Journal Articles

Rituximab Maintenance Treatment for a Maximum of 5 Years in Follicular Lymphoma: Final Results of the Randomized Phase III Trial SAKK 35/03

Christian Taverna, MD, Giovanni Martinelli, MD, Felicitas Hitz, MD, Walter Mingrone, MD, Thomas Pabst, MD PhD, Lidija Cevreska, MD PhD, Auro del Giglio, MD, Anna Vanazzi, MD, Daniele Laszlo, MD, Johann Raats, Daniel Rauch, Daniel Vorobiof, Andreas Lohri, MD, Emanuele Zucca, Celine Rueegsegger, Stephanie - Rondeau, Corinne Rusterholz, Michele Ghielmini

Blood (2018) 132 (Supplement 1): 1601.

https://doi.org/10.1182/blood-2018-99-116864

Published: 2018

Journal Articles

Real-World Data of Nivolumab in Classical Hodgkin Lymphoma: Results from the Italian Expanded Access Programme

Blood (2017) 130 (Supplement 1): 5171.

https://doi.org/10.1182/blood.V130.Suppl_1.5171.5171

Published: 2017

Journal Articles

Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Hodgkin's Lymphoma

Blood (2016) 128 (22): 4161.

https://doi.org/10.1182/blood.V128.22.4161.4161

Published: 2016

Journal Articles

Prognostic Value of End of Treatment FDG-PET Scan in T-Cell Lymphoma, a 20-Year Single Institution Study

Enrico Derenzini, MD PhD, Angela Gueli, MD, Safaa Ramadan, PhD MD, Anna Vanazzi, MD, Simona Sammassimo, MD, Federica Gigli, MD, Niccolo' Frungillo, MD, Riccardo Bruna, MD, Alberto Agazzi, MD, Alberto De Crescenzo, MD, Rocco Pastano, MD, Laura L Travaini, MD, Chiara Grana, MD, Laszlo Daniele, MD, William Arcese, Corrado Tarella, MD

Blood (2016) 128 (22): 3003.

https://doi.org/10.1182/blood.V128.22.3003.3003

Published: 2016

Journal Articles

Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Anaplastic Large Cell Lymphoma

Blood (2016) 128 (22): 3007.

https://doi.org/10.1182/blood.V128.22.3007.3007

Published: 2016

Journal Articles

Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10

Blood (2016) 128 (22): 1099.

https://doi.org/10.1182/blood.V128.22.1099.1099

Published: 2016

Journal Articles

Rituximab Maintenance Treatment For a Maximum Of 5 Years In Follicular Lymphoma: Results Of The Randomized Phase III Trial SAKK 35/03

Christian J. Taverna, MD, Giovanni Martinelli, Felicitas Hitz, Walter Mingrone, Thomas Pabst, MD, Lidija Cevreska, Auro del Giglio, MD, Anna Vanazzi, Daniele Laszlo, Johann Raats, Daniel Rauch, Daniel A. Vorobiof, Andreas Lohri, MD, Emanuele Zucca, MD, Christine Biaggi Rudolf, Stephanie Rondeau, Corinne Rusterholz, Michele Ghielmini, MD

Blood (2013) 122 (21): 508.

https://doi.org/10.1182/blood.V122.21.508.508

Published: 2013

Journal Articles

The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia and Second Malignancy Following Yttrium-90 Ibritumomab Tiuxetan: 10-Year Single-Institution Experience of 138 Consecutive Patients

Anna Vanazzi, Chiara Grana, Daniele Laszlo, Marco Chinol, Mara Negri, Liliana Calabrese, Giovanni Paganelli, Giovanni Martinelli

Blood (2012) 120 (21): 4876.

https://doi.org/10.1182/blood.V120.21.4876.4876

Published: 2012

Journal Articles

Efficacy of 90 yttrium-Ibritumomab Tiuxetan in Extranodal Marginal-Zone Lymphoma,

Anna Vanazzi, Chiara Grana, Cristiano Crosta, Giancarlo Pruneri, Stefania Rizzo, Davide Radice, Antonello Pinto, Liliana Calabrese, Mara Negri, Giovanni Paganelli, Giovanni Martinelli, MD

Blood (2011) 118 (21): 3713.

https://doi.org/10.1182/blood.V118.21.3713.3713

Published: 2011

Journal Articles

A New Induction Combination Therapy (ThalDoDex) for Multiple Myeloma. Preliminary Results of a Phase II Study

Simona Sammassimo, Alberto Agazzi, Simona Bassi, Liliana Calabrese, Paola Bertazzoni, Anna Vanazzi, Angelo Gardellini, Federica Gigli, Giovanna Andreola, Giovanni Martinelli, MD

Blood (2010) 116 (21): 5030.

https://doi.org/10.1182/blood.V116.21.5030.5030

Published: 2010

NARROW

Real-World Venetoclax-Obinutuzumab in 232 Treatment Naive CLL Patients: Feasibility and Tolerability

Long-Term Efficacy of a 6-Month Regimen of Rituximab and Lenalidomide in Follicular Lymphoma Patients in Need of First Therapy: Updated Analysis of the SAKK 35/10 Randomized Trial

Pet-2 Positive during Frontline Therapy: An Early Unfavorable Predictor for Subsequent Salvage High-Dose Chemotherapy (HD-CT) and Autologous Stem Cell Transplant in Relapsed or Refractory Classical Hodgkin Lymphoma

Immune-Related Gene Expression Signatures Identify a Patient's Subset Achieving Durable Complete Response to Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma

Integration of Targeted Gene Expression Profiling and FDG-PET Radiomics Uncovers Radiometabolic Signatures Associated with Outcome in Diffuse Large B-Cell Lymphoma

Follicular Lymphoma Microenvironment Signatures Define Patients Subsets Obtaining Long Term Clinical Benefit after Single-Agent First-Line Anti-CD20 Immunotherapy

Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): The Experience at European Institute of Oncology (EIO)

Lymphoma Occurring during Pregnancy: Obstetric Outcome and Overall Survival in a Series of 19 Patients

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

Integration of Nanostring Profiling and Functional Characterization of Oxidative and Replicative Stress Biomarkers Identifies Poor Prognosis MYC/BCL-2 Positive Diffuse Large B-Cell Lymphoma Subsets, Providing Opportunities for Precision Therapies

Rituximab Maintenance Treatment for a Maximum of 5 Years in Follicular Lymphoma: Final Results of the Randomized Phase III Trial SAKK 35/03

Real-World Data of Nivolumab in Classical Hodgkin Lymphoma: Results from the Italian Expanded Access Programme

Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Hodgkin's Lymphoma

Prognostic Value of End of Treatment FDG-PET Scan in T-Cell Lymphoma, a 20-Year Single Institution Study

Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Anaplastic Large Cell Lymphoma

Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10

Rituximab Maintenance Treatment For a Maximum Of 5 Years In Follicular Lymphoma: Results Of The Randomized Phase III Trial SAKK 35/03

The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia and Second Malignancy Following Yttrium-90 Ibritumomab Tiuxetan: 10-Year Single-Institution Experience of 138 Consecutive Patients

Efficacy of 90 yttrium-Ibritumomab Tiuxetan in Extranodal Marginal-Zone Lymphoma,

A New Induction Combination Therapy (ThalDoDex) for Multiple Myeloma. Preliminary Results of a Phase II Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only